Contineum Therapeutics (CTNM) Interest Expenses (2023)

Contineum Therapeutics' Interest Expenses history runs 4 years deep, the most recent figure standing at $41.7 million for Q2 2026.

• In Q2 2026, Interest Expenses rose 505.14% year-over-year to $41.7 million; the TTM figure through Jun 2026 stood at $41.7 million (up 505.14% YoY), while the FY2025 annual figure was $48.0 million, up 35.03% from the prior year.
• Interest Expenses for Q2 2026 stood at $41.7 million, up from $24.0 million in the prior quarter.
• The five-year high for Interest Expenses was $41.7 million in Q2 2026, with the low at -$58000.0 in Q4 2023.
• The 4-year median for Interest Expenses is $6.9 million (2025), against an average of $11.6 million.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses soared 29271.74% in 2024, then tumbled 73.1% in 2025.
• Contineum Therapeutics' Interest Expenses stood at -$58000.0 in 2023, then surged by 317.24% to $126000.0 in 2024, then soared by 576.98% to $853000.0 in 2025, then soared by 4787.92% to $41.7 million in 2026.
• Business Quant data shows CTNM's Interest Expenses at $41.7 million in Q2 2026, $24.0 million in Q1 2026, and $853000.0 in Q4 2025.